Belizatinib (Synonyms: TSR-011) |
| Catalog No.GC19063 |
벨리자티닙은 야생형 재조합 ALK 키나아제에 대한 IC50이 0.7nM인 ALK 및 TRKA, TRKB 및 TRKC의 경구 이중 강력한 억제제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1357920-84-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase.
TSR-011 has antitumour activity in the clinical trials.
TSR-011 exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models[1].
References:
[1]. Sullivan I, et al. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016 Jan;8(1):32-47.
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *